

The prevalence, patterns and impact of irritable bowel syndrome in a population of 40 000 subjects

Alimentary Pharmacology and Therapeutics

17, 643-650

DOI: [10.1046/j.1365-2036.2003.01456.x](https://doi.org/10.1046/j.1365-2036.2003.01456.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Aerophagia and intestinal gas. Current Treatment Options in Gastroenterology, 2002, 5, 259-265.	0.3	6
2	Tegaserod. Drugs, 2003, 63, 1101-1120.	4.9	37
3	From comic relief to real understanding; how intestinal gas causes symptoms. Gut, 2003, 52, 1659-1661.	6.1	24
4	The Burden of Illness of Irritable Bowel Syndrome: Current Challenges and Hope for the Future. Journal of Managed Care Pharmacy, 2004, 10, 299-309.	2.2	166
5	Irritable bowel syndrome. British Medical Bulletin, 2004, 72, 15-29.	2.7	59
6	Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. Alimentary Pharmacology and Therapeutics, 2004, 20, 339-345.	1.9	122
7	The validity and accuracy of the Work Productivity and Activity Impairment questionnaire - irritable bowel syndrome version (WPAI:IBS). Alimentary Pharmacology and Therapeutics, 2004, 20, 459-467.	1.9	166
9	How to improve drug development for functional disorders. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2004, 18, 787-796.	1.0	7
10	Definition and epidemiology of functional gastrointestinal disorders. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2004, 18, 613-631.	1.0	120
11	Irritable bowel syndrome in general practice: an overview. Scandinavian Journal of Gastroenterology, 2004, 39, 17-22.	0.6	18
12	Irritable bowel syndrome and surgery: A multivariable analysis. Gastroenterology, 2004, 126, 1665-1673.	0.6	216
13	Unnecessary abdominal and back surgery in irritable bowel syndrome: time to stem the flood now?. Gastroenterology, 2004, 126, 1899-1903.	0.6	21
16	Irritable bowel syndrome in France. European Journal of Gastroenterology and Hepatology, 2004, 16, 995-1001.	0.8	84
17	Increased Prevalence of Functional Gastrointestinal Disorders in Panic Disorder: Clinical and Theoretical Implications. CNS Spectrums, 2005, 10, 899-908.	0.7	43
18	Impact of irritable bowel syndrome on patients' lives: development and psychometric documentation of a disease-specific measure for use in clinical trials. European Journal of Gastroenterology and Hepatology, 2005, 17, 411-420.	0.8	52
19	Tegaserod is safe, well tolerated and effective in the treatment of patients with non-diarrhoea irritable bowel syndrome. European Journal of Gastroenterology and Hepatology, 2005, 17, 421-427.	0.8	16
20	A symptom-based approach to making a positive diagnosis of irritable bowel syndrome with constipation. International Journal of Clinical Practice, 2005, 60, 57-63.	0.8	40
21	Irritable bowel syndrome in developing countries - a disorder of civilization or colonization?.. Neurogastroenterology and Motility, 2005, 17, 317-324.	1.6	161

#	ARTICLE	IF	CITATIONS
22	Towards a better understanding of abdominal bloating and distension in functional gastrointestinal disorders. <i>Neurogastroenterology and Motility</i> , 2005, 17, 500-511.	1.6	66
23	Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 11-20.	1.9	33
24	Systematic review: the influence of geography and ethnicity in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 663-676.	1.9	98
25	Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1365-1375.	1.9	413
26	Effect of tegaserod on work and daily activity in irritable bowel syndrome with constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 373-380.	1.9	35
27	Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 935-942.	1.9	149
28	Prevalence of functional gastrointestinal disorders in a population of subjects consulting for gastroesophageal reflux disease in general practice. <i>Gastroenterologie Clinique Et Biologique</i> , 2005, 29, 243-246.	0.9	44
29	Effects of sildenafil on rat irritable bowel syndrome. <i>Therapy: Open Access in Clinical Medicine</i> , 2005, 2, 237-242.	0.2	23
30	Herbal medicine with curcuma and fumitory in the treatment of irritable bowel syndrome: A randomized, placebo-controlled, double-blind clinical trial. <i>Scandinavian Journal of Gastroenterology</i> , 2005, 40, 936-943.	0.6	44
31	Traditional Chinese Medicine Based Subgrouping of Irritable Bowel Syndrome Patients. <i>The American Journal of Chinese Medicine</i> , 2005, 33, 365-379.	1.5	30
32	Visceral Sensitivity and Symptoms in Patients with Constipation- or Diarrhea-predominant Irritable Bowel Syndrome (IBS): Effect of a Low-Fat Intraduodenal Infusion. <i>American Journal of Gastroenterology</i> , 2005, 100, 383-389.	0.2	73
33	Why do we have so few effective drugs for irritable bowel syndrome? A European perspective. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2005, 2, 436-437.	1.7	6
34	Bowel Habit Subtypes and Temporal Patterns in Irritable Bowel Syndrome: Systematic Review. <i>American Journal of Gastroenterology</i> , 2005, 100, 1174-1184.	0.2	134
35	Tegaserod: Long-Term Treatment for Irritable Bowel Syndrome Patients with Constipation in Primary Care. <i>Digestion</i> , 2005, 71, 238-244.	1.2	17
36	Epidemiology of Irritable Bowel Syndrome Among African Americans as Compared With Whites: A Population-Based Study. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 647-653.	2.4	38
37	The Use of Probiotics in Functional Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2005, 34, 533-545.	1.0	19
38	Disturbances of Motility and Visceral Hypersensitivity in Irritable Bowel Syndrome: Biological Markers or Epiphenomenon. <i>Gastroenterology Clinics of North America</i> , 2005, 34, 221-233.	1.0	47
39	Characterization of the Alternating Bowel Habit Subtype in Patients with Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2005, 100, 896-904.	0.2	113

#	ARTICLE	IF	CITATIONS
41	Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. <i>Gastroenterology</i> , 2005, 128, 541-551.	0.6	1,276
42	Prevalence of Functional Gastrointestinal Disorders in Women Who Report Domestic Violence to the Police. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 436-441.	2.4	35
43	Analysis of the Fecal Microbiota of Irritable Bowel Syndrome Patients and Healthy Controls with Real-Time PCR. <i>American Journal of Gastroenterology</i> , 2005, 100, 373-382.	0.2	608
44	Hypothalamic-Pituitary-Gut Axis Dysregulation in Irritable Bowel Syndrome: Plasma Cytokines as a Potential Biomarker?. <i>Gastroenterology</i> , 2006, 130, 304-311.	0.6	544
45	Relationship of Abdominal Bloating to Distention in Irritable Bowel Syndrome and Effect of Bowel Habit. <i>Gastroenterology</i> , 2006, 131, 1003-1010.	0.6	124
48	Irritable bowel syndrome: The burden and unmet needs in Europe. <i>Digestive and Liver Disease</i> , 2006, 38, 717-723.	0.4	80
49	Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: Baseline results from logic (longitudinal outcomes study of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 497 Td	0.2	739
50	Efficacy of an Encapsulated Probiotic Bifidobacterium infantis 35624 in Women with Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2006, 101, 1581-1590.	0.2	739
52	Irritable bowel syndrome: a common condition commonly misunderstood. <i>Gastrointestinal Nursing</i> , 2006, 4, 10-11.	0.0	2
53	Quality of life of patients with irritable bowel syndrome is low compared to others with chronic diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 475-481.	0.8	29
54	Selective Processing of Gastrointestinal Symptom-related Stimuli in Irritable Bowel Syndrome. <i>Psychosomatic Medicine</i> , 2006, 68, 758-761.	1.3	34
55	The Role of Fiber in the Treatment of Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 104-108.	1.1	39
56	Irritable bowel syndrome: anxiety in gastroenterology. <i>British Journal of Hospital Medicine (London)</i> , Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 497 Td	0.2	2
57	The Effect of a Nonabsorbed Oral Antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome. <i>Annals of Internal Medicine</i> , 2006, 145, 557.	2.0	417
58	Epidemiology of the functional gastrointestinal disorders diagnosed according to Rome II criteria: an Australian population-based study. <i>Internal Medicine Journal</i> , 2006, 36, 28-36.	0.5	95
59	Performance of the EQ-5D in Patients with Irritable Bowel Syndrome. <i>Value in Health</i> , 2006, 9, 90-97.	0.1	52
60	Influence of acute serotonin reuptake inhibition on colonic sensorimotor function in man. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 265-274.	1.9	63
61	Placebo- and paracetamol-controlled study on the efficacy and tolerability of hyoscine butylbromide in the treatment of patients with recurrent crampy abdominal pain. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 1741-1748.	1.9	37

#	ARTICLE	IF	CITATIONS
62	Predictive factors of irritable bowel syndrome improvement: 1-year prospective evaluation in 400 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 815-826.	1.9	29
63	Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome - a European perspective. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 207-236.	1.9	36
64	Systematic review: the efficacy of treatments for irritable bowel syndrome - a European perspective. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 183-205.	1.9	141
65	Pilot study of the efficacy of renzapride on gastrointestinal motility and symptoms in patients with constipation-predominant irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 1655-1665.	1.9	48
66	Prevalence and management of abdominal cramping and pain: a multinational survey. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 411-419.	1.9	55
67	A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 869-878.	1.9	18
68	Physical and psychological co-morbidity in irritable bowel syndrome: a matched cohort study using the General Practice Research Database. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 879-886.	1.9	71
69	Prevalence, Sociodemography, and Quality of Life of Older Versus Younger Patients with Irritable Bowel Syndrome: A Population-Based Study. <i>Digestive Diseases and Sciences</i> , 2006, 51, 446-453.	1.1	62
70	Studying the Overlap Between IBS and GERD: A Systematic Review of the Literature. <i>Digestive Diseases and Sciences</i> , 2006, 51, 2113-2120.	1.1	88
71	Symptom patterns and relative distribution of functional bowel disorders in 1,023 gastroenterology patients in Iran. <i>International Journal of Colorectal Disease</i> , 2006, 21, 814-825.	1.0	20
72	Gastroesophageal reflux disease and irritable bowel syndrome: A common overlap syndrome. <i>Current Gastroenterology Reports</i> , 2006, 8, 261-265.	1.1	23
73	???My patients are the sickest???. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 465-467.	0.8	0
74	Prevalence, comorbidity and impact of irritable bowel syndrome in Norway. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 650-656.	0.6	115
75	Self-help interventions in irritable bowel syndrome. <i>Gut</i> , 2006, 55, 603-604.	6.1	10
76	Functional disorders--a cause of increasing work absence?. <i>Occupational Medicine</i> , 2006, 57, 2-3.	0.8	1
77	Pharmacological Treatment of the Irritable Bowel Syndrome and Other Functional Bowel Disorders. <i>Digestion</i> , 2006, 73, 28-37.	1.2	11
78	Germs, Gas and the Gut; the Evolving Role of the Enteric Flora in IBS. <i>American Journal of Gastroenterology</i> , 2006, 101, 334-335.	0.2	31
79	A randomised controlled trial of self-help interventions in patients with a primary care diagnosis of irritable bowel syndrome. <i>Gut</i> , 2006, 55, 643-648.	6.1	85

#	ARTICLE	IF	CITATIONS
80	Chronic diarrhoea. <i>Gut</i> , 2007, 56, 1756-1757.	6.1	1
81	Comorbidity and use of health-care services among irritable bowel syndrome sufferers. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 799-806.	0.6	48
82	Cholangiocarcinoma and its management. <i>Gut</i> , 2007, 56, 1755-1756.	6.1	38
83	Screening for coeliac disease in patients fulfilling the Rome II criteria for irritable bowel syndrome in a secondary care hospital in The Netherlands: a prospective observational study. <i>Gut</i> , 2007, 56, 444-445.	6.1	18
85	Women With Irritable Bowel Syndrome and Their Perception of a Good Quality of Life. <i>Gastroenterology Nursing</i> , 2007, 30, 74-82.	0.2	24
86	Guidelines on the irritable bowel syndrome: mechanisms and practical management. <i>Gut</i> , 2007, 56, 1770-1798.	6.1	677
89	Irritable Bowel Syndrome. <i>Clinical Drug Investigation</i> , 2007, 27, 15-33.	1.1	25
90	It takes guts to talk about bowels: The Gut Trust. <i>Gastrointestinal Nursing</i> , 2007, 5, 14-16.	0.0	0
91	Extracirculatory effects of noise of various frequency spectra in humans-effect of pink and blue noise on gastric myoelectrical activity and gastrointestinal passage of nutrients. <i>Journal of Smooth Muscle Research</i> , 2007, 43, 25-42.	0.7	5
92	Prevalence, Impact and Attitudes Toward Lower Gastrointestinal Dysmotility and Sensory Symptoms, and Their Treatment in Canada: A Descriptive Study. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2007, 21, 31-37.	1.8	12
93	Development and psychometric testing of the Visual Analogue Scale for Irritable Bowel Syndrome (VAS-IBS). <i>BMC Gastroenterology</i> , 2007, 7, 16.	0.8	105
94	The "Con"™ case. The Rome Process and Functional Gastrointestinal Disorders: the barbarians are at the gate!. <i>Neurogastroenterology and Motility</i> , 2007, 19, 793-797.	1.6	31
95	Positive association between gastroesophageal reflux disease and irritable bowel syndrome in a Chinese population. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 1099-1104.	1.9	35
96	Overlap of gastroesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 453-461.	1.9	114
97	Subtyping the irritable bowel syndrome by predominant bowel habit: Rome II versus Rome III. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 953-961.	1.9	66
98	Economic Evaluation of Tegaserod vs. Placebo in the Treatment of Patients with Irritable Bowel Syndrome: An Analysis of the TENOR Study. <i>Value in Health</i> , 2007, 10, 238-246.	0.1	15
99	Preliminary Study of a Self-Administered Treatment for Irritable Bowel Syndrome: Comparison to a Wait List Control Group. <i>Applied Psychophysiology Biofeedback</i> , 2007, 32, 111-119.	1.0	38
101	A Survey about Irritable Bowel Syndrome in South Korea. <i>Digestive Diseases and Sciences</i> , 2008, 53, 704-711.	1.1	43

#	ARTICLE	IF	CITATIONS
102	Identification of Patients with Non-D, Non-C Irritable Bowel Syndrome and Treatment with Renzapride: An Exploratory, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. <i>Digestive Diseases and Sciences</i> , 2008, 53, 3191-3200.	1.1	15
103	Evaluation of the Birmingham IBS symptom questionnaire. <i>BMC Gastroenterology</i> , 2008, 8, 30.	0.8	76
104	LCâ€“Tandem-MS Development and Validation for the Determination of Tegaserod in Beagle Dog Plasma and Its Application to a Pharmacokinetic Study. <i>Chromatographia</i> , 2008, 67, 801-806.	0.7	2
105	Afferent hypersensitivity in a mouse model of postâ€“inflammatory gut dysfunction: role of altered serotonin metabolism. <i>Journal of Physiology</i> , 2008, 586, 4517-4530.	1.3	78
106	Review article: the psychoneuroimmunology of irritable bowel syndrome â€“ an exploration of interactions between psychological, neurological and immunological observations. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 830-840.	1.9	53
107	Fluctuation of gastrointestinal symptoms in the community: a 10â€“year longitudinal followâ€“up study. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 1013-1020.	1.9	51
108	The trials and tribulations of drug development for functional gastrointestinal disorders. <i>Neurogastroenterology and Motility</i> , 2008, 20, 130-138.	1.6	5
109	Treatments for irritable bowel syndrome: patients' attitudes and acceptability. <i>BMC Complementary and Alternative Medicine</i> , 2008, 8, 65.	3.7	49
110	An examination of subgroup classification in irritable bowel syndrome patients over time: A prospective study. <i>International Journal of Nursing Studies</i> , 2008, 45, 1715-1720.	2.5	12
112	Probiotics: Which and When?. <i>Digestive Diseases</i> , 2008, 26, 175-182.	0.8	27
113	Gallstones, cholecystectomy and irritable bowel syndrome (IBS). <i>Digestive and Liver Disease</i> , 2008, 40, 944-950.	0.4	30
114	Enhanced Cholinergic-Mediated Increase in the Pro-Inflammatory Cytokine IL-6 in Irritable Bowel Syndrome: Role of Muscarinic Receptors. <i>American Journal of Gastroenterology</i> , 2008, 103, 2570-2576.	0.2	122
115	Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis. <i>Gut</i> , 2008, 57, 1545-1553.	6.1	124
116	Gastrointestinal Microbiota in Irritable Bowel Syndrome: Their Role in Its Pathogenesis and Treatment. <i>American Journal of Gastroenterology</i> , 2008, 103, 1557-1567.	0.2	160
117	Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1663-1670.	1.9	15
118	Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2008, 337, a2313-a2313.	2.4	454
119	Patients' explanatory models for irritable bowel syndrome: symptoms and treatment more important than explaining aetiology. <i>Family Practice</i> , 2008, 26, 40-47.	0.8	45
120	Irritable Bowel Syndrome: A 10-Yr Natural History of Symptoms and Factors That Influence Consultation Behavior. <i>American Journal of Gastroenterology</i> , 2008, 103, 1229-1239.	0.2	194

#	ARTICLE	IF	CITATIONS
121	Tegaserod for Female Patients Suffering From IBS With Mixed Bowel Habits or Constipation: A Randomized Controlled Trial. <i>American Journal of Gastroenterology</i> , 2008, 103, 1217-1225.	0.2	53
122	Behavioral and Complementary Approaches for the Treatment of Irritable Bowel Syndrome. <i>Nutrition in Clinical Practice</i> , 2008, 23, 284-292.	1.1	42
123	The Effects of Exercise upon Symptoms and Quality of Life in Patients Diagnosed with Irritable Bowel Syndrome: A Randomised Controlled Trial. <i>International Journal of Sports Medicine</i> , 2008, 29, 778-782.	0.8	78
124	GPs' explanatory models for irritable bowel syndrome: a mismatch with patient models?. <i>Family Practice</i> , 2008, 26, 34-39.	0.8	33
125	Will the History and Physical Examination Help Establish That Irritable Bowel Syndrome Is Causing This Patient's Lower Gastrointestinal Tract Symptoms?. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 1793.	3.8	98
126	Healthcare seeking in gastro-oesophageal reflux disease: a qualitative study. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 269-275.	0.8	21
127	Prevalence of Abdominal and Pelvic Surgeries in Patients With Irritable Bowel Syndrome: Comparison Between Caucasian and African Americans. <i>American Journal of the Medical Sciences</i> , 2008, 335, 82-88.	0.4	5
128	Determinants of Quality of Life in Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 1003-1009.	1.1	37
129	Irritable bowel syndrome: an international study of symptoms in eight countries. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 659-667.	0.8	33
130	Prevalence of gastrointestinal symptoms in patients with chronic obstructive pulmonary disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 335-341.	0.8	28
131	Efficacy of 5-HT3 Antagonists and 5-HT4 Agonists in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2009, 104, 1831-1843.	0.2	235
132	Rectal Visceral Sensitivity in Women with Irritable Bowel Syndrome without Psychiatric Comorbidity Compared with Healthy Volunteers. <i>Gastroenterology Research and Practice</i> , 2009, 2009, 1-8.	0.7	8
133	The language of medicine: words as servants and scoundrels. <i>Clinical Medicine</i> , 2009, 9, 131-135.	0.8	12
134	Prevalence and risk factors of irritable bowel syndrome in Korean adolescent girls: A school-based study. <i>International Journal of Nursing Studies</i> , 2009, 46, 77-85.	2.5	47
139	The challenge of cross-cultural, multinational research: potential benefits in the functional gastrointestinal disorders. <i>Neurogastroenterology and Motility</i> , 2009, 21, 351-360.	1.6	31
140	Clinical trial: the effects of a fermented milk product containing <i>Bifidobacterium lactis</i> DN1731 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 104-114.	1.9	289
141	Health care seeking for abdominal bloating and visible distention. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 775-783.	1.9	4
142	Epidemiology of irritable bowel syndrome in Asia: Something old, something new, something borrowed. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2009, 24, 1601-1607.	1.4	144

#	ARTICLE	IF	CITATIONS
143	Irritable bowel syndrome: Role of food in pathogenesis and management. <i>Journal of Digestive Diseases</i> , 2009, 10, 237-246.	0.7	76
144	Prebiotics for irritable bowel syndrome. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 487-492.	1.4	8
146	Irritable bowel syndrome: Novel views on the epidemiology and potential risk factors. <i>Digestive and Liver Disease</i> , 2009, 41, 772-780.	0.4	95
147	Emerging drugs for irritable bowel syndrome. <i>Expert Opinion on Emerging Drugs</i> , 2009, 14, 673-685.	1.0	7
148	Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. <i>Gut</i> , 2009, 58, 367-378.	6.1	486
149	Development and Evaluation of a pH-Dependent Sustained Release Tablet for Irritable Bowel Syndrome. <i>Drug Development and Industrial Pharmacy</i> , 2009, 35, 57-64.	0.9	4
151	Do fluctuations in ovarian hormones affect gastrointestinal symptoms in women with irritable bowel syndrome?. <i>Gender Medicine</i> , 2009, 6, 152-167.	1.4	116
152	Impact of Bloating and Distention in Irritable Bowel Syndrome: Have We Wandered too far From the Manning Creed?. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 7-8.	2.4	13
154	Psyllium. , 2009, , .		0
155	Disease burden of post-infectious irritable bowel syndrome in The Netherlands. <i>Epidemiology and Infection</i> , 2010, 138, 1650-1656.	1.0	70
156	A Holistic Approach for Planning Care of Patients With Irritable Bowel Syndrome. <i>Gastroenterology Nursing</i> , 2010, 33, 98-108.	0.2	10
157	Dysfunctional Cognitions, Anxiety and Depression in Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, e236-e241.	1.1	78
158	The use of probiotics in gastrointestinal diseases. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2010, 3, 105-113.	0.2	8
159	New Clinical Method for Distinguishing D-IBS from Other Gastrointestinal Conditions Causing Diarrhea: The LA/IBS Diagnostic Strategy. <i>Digestive Diseases and Sciences</i> , 2010, 55, 145-149.	1.1	30
160	Evaluating Breath Methane as a Diagnostic Test for Constipation-Predominant IBS. <i>Digestive Diseases and Sciences</i> , 2010, 55, 398-403.	1.1	74
161	Polycystic Ovary Syndrome Is Associated with an Increased Prevalence of Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1085-1089.	1.1	34
162	Proton Pump Inhibitor Therapy Does Not Affect Hydrogen Production on Lactulose Breath Test in Subjects with IBS. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2302-2308.	1.1	30
163	Abnormal Small-Intestinal Endocrine Cells in Patients with Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2010, 55, 3508-3513.	1.1	44

#	ARTICLE	IF	CITATIONS
164	Abnormal Breath Testing in IBS: A Meta-Analysis. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2441-2449.	1.1	140
165	Emotional intelligence and frustration: predictors of quality of life in patients with irritable bowel syndrome. <i>Procedia, Social and Behavioral Sciences</i> , 2010, 5, 827-831.	0.5	6
166	Comparing administrative and survey data for ascertaining cases of irritable bowel syndrome: a population-based investigation. <i>BMC Health Services Research</i> , 2010, 10, 31.	0.9	27
167	How does comorbidity affect cost of health care in patients with irritable bowel syndrome? A cohort study in general practice. <i>BMC Gastroenterology</i> , 2010, 10, 31.	0.8	41
168	Prevalence of mood and anxiety disorder in self reported irritable bowel syndrome (IBS). An epidemiological population based study of women. <i>BMC Gastroenterology</i> , 2010, 10, 88.	0.8	96
169	Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome – a randomized, double-blind, placebo-controlled study. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 615-624.	1.9	65
170	Drug treatment of chronic/intermittent abdominal cramping and pain: a multi-national survey on usage and attitudes. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 472-477.	1.9	6
171	Dyspepsia and irritable bowel syndrome in China: a population-based endoscopy study of prevalence and impact. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 562-572.	1.9	70
172	Stability of the irritable bowel syndrome and subgroups as measured by three diagnostic criteria – a 10-year follow-up study. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 670-680.	1.9	46
173	Ameliorating effects of mirtazapine on visceral hypersensitivity in rats with neonatal colon sensitivity. <i>Neurogastroenterology and Motility</i> , 2010, 22, 1022.	1.6	15
174	Effect of otilonium bromide on contractile patterns in the human sigmoid colon. <i>Neurogastroenterology and Motility</i> , 2010, 22, e180-e191.	1.6	26
175	The Current Prevalence of Irritable Bowel Syndrome in Asia. <i>Journal of Neurogastroenterology and Motility</i> , 2010, 16, 389-400.	0.8	95
176	Irritable Bowel Syndrome and Co-morbid Gastrointestinal and Extra-gastrointestinal Functional Syndromes. <i>Journal of Neurogastroenterology and Motility</i> , 2010, 16, 113-119.	0.8	62
177	A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. <i>World Journal of Gastroenterology</i> , 2010, 16, 547.	1.4	70
178	The Role of Probiotics in the Treatment of Irritable Bowel Syndrome. , 2010, , 513-528.		3
179	Treating irritable bowel syndrome with probiotics: the evidence. <i>Proceedings of the Nutrition Society</i> , 2010, 69, 187-194.	0.4	51
180	Effects of a health program comprising reassurance, diet management, probiotics administration and regular exercise on symptoms and quality of life in patients with irritable bowel syndrome. <i>Gastroenterology Insights</i> , 2010, 2, 6.	0.7	19
181	IBS: an epigenetic perspective. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 465-471.	8.2	75

#	ARTICLE	IF	CITATIONS
182	Functional bowel disorders in Iranian population using Rome III criteria. Saudi Journal of Gastroenterology, 2010, 16, 154.	0.5	95
183	Evaluating a Bacterial Hypothesis in IBS Using a Modification of Koch's Postulates: Part 1. American Journal of Gastroenterology, 2010, 105, 718-721.	0.2	29
184	Bacteria, genetics and irritable bowel syndrome. Expert Review of Gastroenterology and Hepatology, 2010, 4, 271-276.	1.4	8
185	Prevalence of Uninvestigated Dyspepsia 8 Years After a Large Waterborne Outbreak of Bacterial Dysentery: A Cohort Study. Gastroenterology, 2010, 138, 1727-1736.	0.6	75
186	Pathogenic Factors Involved in the Development of Irritable Bowel Syndrome: Focus on a Microbial Role. Infectious Disease Clinics of North America, 2010, 24, 961-975.	1.9	28
187	Irritable Bowel Syndrome—Type Symptoms in Patients With Inflammatory Bowel Disease: A Real Association or Reflection of Occult Inflammation?. American Journal of Gastroenterology, 2010, 105, 1789-1794.	0.2	204
188	Chromogranin A as a possible tool in the diagnosis of irritable bowel syndrome. Scandinavian Journal of Gastroenterology, 2010, 45, 1435-1439.	0.6	61
189	Societal costs for irritable bowel syndrome – a population based study. Scandinavian Journal of Gastroenterology, 2010, 45, 582-591.	0.6	49
190	Health-related quality of life, work productivity and health care resource use associated with constipation predominant irritable bowel syndrome. Current Medical Research and Opinion, 2011, 27, 2213-2222.	0.9	56
191	Traditional Thoughts on the Pathophysiology of Irritable Bowel Syndrome. Gastroenterology Clinics of North America, 2011, 40, 21-43.	1.0	42
192	Epidemiology of IBS. Gastroenterology Clinics of North America, 2011, 40, 1-10.	1.0	145
193	Magnetic resonance imaging of rectal volume in patients with irritable bowel syndrome. Digestive and Liver Disease, 2011, 43, 529-534.	0.4	2
194	Irritable Bowel Syndrome. Primary Care - Clinics in Office Practice, 2011, 38, 433-447.	0.7	15
195	Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. The Cochrane Library, 2013, 2013, CD003460.	1.5	217
196	Do interactions between stress and immune responses lead to symptom exacerbations in irritable bowel syndrome?. Brain, Behavior, and Immunity, 2011, 25, 1333-1341.	2.0	113
197	Special Considerations for Women with IBD. Gastroenterology Clinics of North America, 2011, 40, 387-398.	1.0	21
198	Factors associated with irritable bowel syndrome symptoms in hemodialysis patients. World Journal of Gastroenterology, 2011, 17, 1976.	1.4	11
199	Pattern of irritable bowel syndrome and its impact on quality of life in primary health care center attendees, Suez governorate, Egypt. Pan African Medical Journal, 2011, 9, 5.	0.3	29

#	ARTICLE	IF	CITATIONS
200	Prevalence of Irritable Bowel Syndrome: A Community Based Study From Northern India. <i>Journal of Neurogastroenterology and Motility</i> , 2011, 17, 82-87.	0.8	83
201	Are Food Constituents Relevant to the Irritable Bowel Syndrome in Young Adults? - A Rome III Based Prevalence Study of the Korean Medical Students. <i>Journal of Neurogastroenterology and Motility</i> , 2011, 17, 294-299.	0.8	29
202	Postinfectious Functional Gastrointestinal Disorders. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, S102-S105.	1.1	26
203	PhyloChip microarray analysis reveals altered gastrointestinal microbial communities in a rat model of colonic hypersensitivity. <i>Neurogastroenterology and Motility</i> , 2011, 23, 169-e42.	1.6	36
204	Treatment of IBS-D with 5-HT ₃ receptor antagonists vs spasmolytic agents: similar therapeutical effects from heterogeneous pharmacological targets. <i>Neurogastroenterology and Motility</i> , 2011, 23, 1051-1055.	1.6	11
205	Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 432-442.	1.9	96
206	Quantification of fructans, galacto-oligosaccharides and other short-chain carbohydrates in processed grains and cereals. <i>Journal of Human Nutrition and Dietetics</i> , 2011, 24, 154-176.	1.3	274
207	Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. <i>Journal of Human Nutrition and Dietetics</i> , 2011, 24, 487-495.	1.3	350
209	Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. <i>Journal of Gastroenterology</i> , 2011, 46, 421-431.	2.3	166
210	Evaluation of gastrointestinal symptoms in different patient groups using the visual analogue scale for irritable bowel syndrome (VAS-IBS). <i>BMC Gastroenterology</i> , 2011, 11, 122.	0.8	41
211	Do gastrointestinal complaints increase the risk for subsequent medically certified long-term sickness absence? The HUSK study. <i>BMC Gastroenterology</i> , 2011, 11, 88.	0.8	4
212	The frequency of microscopic and focal active colitis in patients with irritable bowel syndrome. <i>BMC Gastroenterology</i> , 2011, 11, 96.	0.8	26
213	Confidence-Based Learning CME: Overcoming Barriers in Irritable Bowel Syndrome With Constipation. <i>Journal of Continuing Education in the Health Professions</i> , 2011, 31, 157-164.	0.4	5
214	Long-term impact of irritable bowel syndrome: a qualitative study. <i>Primary Health Care Research and Development</i> , 2011, 12, 52-67.	0.5	39
215	Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes. <i>Current Medical Research and Opinion</i> , 2011, 27, 503-512.	0.9	7
216	Benefits from Long-Term Treatment in Irritable Bowel Syndrome. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-6.	0.7	20
217	Psychopharmacological Treatment and Psychological Interventions in Irritable Bowel Syndrome. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-11.	0.7	19
218	The Epidemiology of Functional Gastrointestinal Disorders in Mexico: A Population-Based Study. <i>Gastroenterology Research and Practice</i> , 2012, 2012, 1-8.	0.7	75

#	ARTICLE	IF	CITATIONS
219	Protective Nutrients. Nutrition Today, 2012, 47, 110-122.	0.6	0
220	Visceral pain. Current Opinion in Supportive and Palliative Care, 2012, 6, 17-26.	0.5	161
221	Role of Radiologic Imaging in Irritable Bowel Syndrome: Evidence-based Review. Radiology, 2012, 262, 485-494.	3.6	32
222	Editorial: "Irritable Bowel Symptoms" in Inflammatory Bowel Disease: Diagnostic Uncertainty Meets Pathological Reality. American Journal of Gastroenterology, 2012, 107, 1483-1485.	0.2	10
223	Linacotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety. American Journal of Gastroenterology, 2012, 107, 1702-1712.	0.2	374
224	A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linacotide in Irritable Bowel Syndrome With Constipation. American Journal of Gastroenterology, 2012, 107, 1714-1724.	0.2	318
225	Burden of constipation-predominant irritable bowel syndrome (IBS-C) in France, Italy, and the United Kingdom. Clinical and Experimental Gastroenterology, 2012, 5, 203.	1.0	17
226	A Global Perspective on Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 2012, 46, 356-366.	1.1	124
227	"Pre-cebo". Journal of Clinical Gastroenterology, 2012, 46, 686-690.	1.1	14
228	Diagnostic criteria in IBS: useful or not?. Neurogastroenterology and Motility, 2012, 24, 791-801.	1.6	33
229	Clinical Trial: Transcutaneous Interferential Electrical Stimulation in Individuals with Irritable Bowel Syndrome " A Prospective Double-Blind Randomized Study. Digestion, 2012, 86, 86-93.	1.2	26
230	Prevalence of disturbed bowel functions and its association with disturbed bladder and sexual functions in the male population. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1738-1744.	1.4	10
231	Probiotics in the Management of Functional Bowel Disorders. Gastroenterology Clinics of North America, 2012, 41, 805-819.	1.0	20
232	Increased Risk of Miscarriage and Ectopic Pregnancy Among Women With Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology, 2012, 10, 902-909.	2.4	20
233	Prevalence, comorbidity, and risk factors for functional bowel symptoms: a population-based survey in Northern Norway. Scandinavian Journal of Gastroenterology, 2012, 47, 1274-1282.	0.6	27
234	Anxiety-depressive disorders among irritable bowel syndrome patients in Guilan, Iran. BMC Research Notes, 2012, 5, 112.	0.6	24
235	Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months. Alimentary Pharmacology and Therapeutics, 2012, 36, 1084-1093.	1.9	52
237	Natural history of functional gastrointestinal disorders: Comparison of two longitudinal population-based studies. Digestive and Liver Disease, 2012, 44, 211-217.	0.4	37

#	ARTICLE	IF	CITATIONS
238	The Global Perspective on Irritable Bowel Syndrome: A Rome Foundationâ€“World Gastroenterology Organisation Symposium. <i>American Journal of Gastroenterology</i> , 2012, 107, 1602-1609.	0.2	37
239	Subtypes and Symptomatology of Irritable Bowel Syndrome in Children and Adolescents: A School-based Survey Using Rome III Criteria. <i>Journal of Neurogastroenterology and Motility</i> , 2012, 18, 298-304.	0.8	56
240	Irritable bowel syndrome: Diagnosis and pathogenesis. <i>World Journal of Gastroenterology</i> , 2012, 18, 5151-5163.	1.4	145
241	Linacotide: evidence for its potential use in irritable bowel syndrome and chronic constipation. <i>Core Evidence</i> , 2012, 7, 39.	4.7	5
242	Irritable bowel syndrome the role of gut neuroendocrine peptides. <i>Frontiers in Bioscience - Elite</i> , 2012, E4, 2683-2700.	0.9	55
243	Asimadoline and its potential for the treatment of diarrhea-predominant irritable bowel syndrome: a review. <i>Clinical and Experimental Gastroenterology</i> , 2012, 5, 1.	1.0	35
244	Low Densities of Serotonin and Peptide YY Cells in the Colon of Patients with Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2012, 57, 873-878.	1.1	64
245	Irritable bowel syndrome and other gastrointestinal disorders: evaluating self-medication in an Asian community setting. <i>International Journal of Clinical Pharmacy</i> , 2012, 34, 561-568.	1.0	10
246	Distinct microbial populations exist in the mucosaâ€“associated microbiota of subâ€“groups of irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2012, 24, 31-39.	1.6	180
247	Validity and reliability of the Malayâ€“language translation of the Rome III Diagnostic Questionnaire for irritable bowel syndrome. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 746-750.	1.4	20
248	The spectrum of functional gastrointestinal disorders in a tertiary referral clinic in Ireland. <i>Irish Journal of Medical Science</i> , 2012, 181, 81-86.	0.8	13
249	Perspectives on irritable bowel syndrome: where have we been? Where are we now?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 3-7.	1.4	3
250	Constellaâ„¢(EU)â€“Linzessâ„¢(USA): the last milestone in the long journey of the peptide linacotide and its implications for the future of peptide drugs. <i>Future Medicinal Chemistry</i> , 2013, 5, 291-300.	1.1	10
251	GP perspectives of irritable bowel syndrome â€“ an accepted illness, but management deviates from guidelines: a qualitative study. <i>BMC Family Practice</i> , 2013, 14, 92.	2.9	26
252	A randomised controlled trial of a probiotic â€“functional foodâ€™ in the management of irritable bowel syndrome. <i>BMC Gastroenterology</i> , 2013, 13, 45.	0.8	78
253	Mindfulness-Based Stress Reduction for the Treatment of Irritable Bowel Syndrome Symptoms: A Randomized Wait-list Controlled Trial. <i>International Journal of Behavioral Medicine</i> , 2013, 20, 385-396.	0.8	142
254	Colonic gas transit in patients with bloating: the effect of an electromechanical stimulator of the abdominal wall. <i>Techniques in Coloproctology</i> , 2013, 17, 405-410.	0.8	9
255	How can we achieve relief of bowel and abdominal symptoms for patients with irritable bowel syndrome with constipation?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2013, 7, 21-26.	1.4	3

#	ARTICLE	IF	CITATIONS
256	The low FODMAP diet improves gastrointestinal symptoms in patients with irritable bowel syndrome: a prospective study. <i>International Journal of Clinical Practice</i> , 2013, 67, 895-903.	0.8	252
257	Cognitive and affective reassurance and patient outcomes in primary care: A systematic review. <i>Pain</i> , 2013, 154, 2407-2416.	2.0	156
258	Posterior laryngitis: a disease with different aetiologies affecting health-related quality of life: a prospective caseâ€“control study. <i>BMC Ear, Nose and Throat Disorders</i> , 2013, 13, 11.	2.6	2
259	Comparison of Manning, Rome I, II, and III, and Asian diagnostic criteria: Report of the Multicentric Indian Irritable Bowel Syndrome (MIIBS) study. <i>Indian Journal of Gastroenterology</i> , 2013, 32, 369-375.	0.7	32
260	Patients Suspected of Irritable Bowel Syndromeâ€“Cross-Sectional Study Exploring the Sensitivity of Rome III Criteria in Primary Care. <i>American Journal of Gastroenterology</i> , 2013, 108, 972-980.	0.2	46
261	Targeted screening for Coeliac Disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information. <i>European Journal of Health Economics</i> , 2013, 14, 947-957.	1.4	14
262	Low prevalence of irritable bowel syndrome in primary health care in four Swedish counties. <i>Scandinavian Journal of Primary Health Care</i> , 2013, 31, 132-137.	0.6	10
263	The epidemiology of irritable bowel syndrome in Denmark. A population-based survey in adults â‰¥50 years of age. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 523-529.	0.6	60
264	Cost-Effectiveness of Linaclotide Compared to Antidepressants in the Treatment of Irritable Bowel Syndrome with Constipation in Scotland. <i>Value in Health</i> , 2013, 16, A497.	0.1	1
265	Psychosocial predictors of irritable bowel syndrome diagnosis and symptom severity. <i>Journal of Psychosomatic Research</i> , 2013, 75, 467-474.	1.2	40
266	A Positive Diagnostic Strategy Is Noninferior to a Strategy of Exclusion for Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 956-962.e1.	2.4	63
267	Randomised clinical trials: linaclotide phase 3 studies in <sc>IBS</sc>â€“ a prespecified further analysis based on European Medicines Agencyâ€“specified endpoints. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 49-61.	1.9	115
268	Microencapsulated sodium butyrate reduces the frequency of abdominal pain in patients with irritable bowel syndrome. <i>Colorectal Disease</i> , 2013, 15, 204-209.	0.7	56
269	Low-grade inflammation in the rectum of patients with sporadic irritable bowel syndrome. <i>Molecular Medicine Reports</i> , 2013, 7, 1081-1085.	1.1	22
271	What should be the primary end point in irritable bowel syndrome?. <i>Clinical Investigation</i> , 2013, 3, 131-136.	0.0	1
273	The prevalence of irritable bowel symptoms in a population of shopping mall visitors in Santiago de Chile. <i>Revista De GastroenterologÃa De MÃ©xico (English Edition)</i> , 2013, 78, 203-210.	0.1	4
274	Mental Strain and Chronic Stress among University Students with Symptoms of Irritable Bowel Syndrome. <i>Gastroenterology Research and Practice</i> , 2013, 2013, 1-8.	0.7	27
275	Life Course Study of the Etiology of Self-Reported Irritable Bowel Syndrome in the 1958 British Birth Cohort. <i>Psychosomatic Medicine</i> , 2013, 75, 202-210.	1.3	27

#	ARTICLE	IF	CITATIONS
276	Multicultural considerations in the diagnosis and management of irritable bowel syndrome. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1.	0.8	13
277	Effect of Self-Management Intervention on Cortisol and Daily Stress Levels in Irritable Bowel Syndrome. <i>Biological Research for Nursing</i> , 2013, 15, 26-36.	1.0	19
278	Gut pain & visceral hypersensitivity. <i>British Journal of Pain</i> , 2013, 7, 39-47.	0.7	41
279	An evaluation of the FDA Responder Endpoint for IBS's clinical trials: analysis of data from linaclotide Phase 3 clinical trials. <i>Neurogastroenterology and Motility</i> , 2013, 25, 481.	1.6	24
280	A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation. <i>Current Medical Research and Opinion</i> , 2013, 29, 149-160.	0.9	19
281	On-demand hyoscine butylbromide for the treatment of self-reported functional cramping abdominal pain. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 926-935.	0.6	13
282	Acupuncture for Irritable Bowel Syndrome. <i>Medical Acupuncture</i> , 2013, 25, 78-87.	0.3	4
283	Serotonin and serotonin transporter in the rectum of patients with irritable bowel disease. <i>Molecular Medicine Reports</i> , 2013, 8, 451-455.	1.1	34
284	Effects of dietary guidance on the symptoms, quality of life and habitual dietary intake of patients with irritable bowel syndrome. <i>Molecular Medicine Reports</i> , 2013, 8, 845-852.	1.1	68
285	Psychological well-being and the role of food in healthy middle-aged and older women who have experienced acute gastrointestinal disturbances. <i>British Food Journal</i> , 2013, 115, 711-726.	1.6	0
286	Prevalence and predictors of irritable bowel syndrome among medical students and interns in King Abdulaziz University, Jeddah. <i>Libyan Journal of Medicine</i> , 2013, 8, 21287.	0.8	69
287	Reduced chromogranin A cell density in the ileum of patients with irritable bowel syndrome. <i>Molecular Medicine Reports</i> , 2013, 7, 1241-1244.	1.1	29
288	Irritable Bowel Syndrome and Migraine: Bystanders or Partners?. <i>Journal of Neurogastroenterology and Motility</i> , 2013, 19, 301-311.	0.8	71
289	Is irritable bowel syndrome an organic disorder?. <i>World Journal of Gastroenterology</i> , 2014, 20, 384.	1.4	79
290	Irritable bowel syndrome: A clinical review. <i>World Journal of Gastroenterology</i> , 2014, 20, 12144.	1.4	142
291	Post-traumatic Stress Disorder Is Associated With Irritable Bowel Syndrome in African Americans. <i>Journal of Neurogastroenterology and Motility</i> , 2014, 20, 523-530.	0.8	22
292	Red cell distribution width and mean platelet volume in patients with irritable bowel syndrome. <i>Przegląd Gastroenterologiczny</i> , 2014, 3, 160-163.	0.3	47
294	Therapeutic Effects of Biobran, Modified Arabinoxylan Rice Bran, in Improving Symptoms of Diarrhea Predominant or Mixed Type Irritable Bowel Syndrome: A Pilot, Randomized Controlled Study. <i>Evidence-based Complementary and Alternative Medicine</i> , 2014, 2014, 1-6.	0.5	26

#	ARTICLE	IF	CITATIONS
295	Increased serotonin transporter immunoreactivity intensity in the ileum of patients with irritable bowel disease. <i>Molecular Medicine Reports</i> , 2014, 9, 180-184.	1.1	27
296	Barriers to accurate diagnosis and effective management of heart failure have not changed in the past 10 years: a qualitative study and national survey. <i>BMJ Open</i> , 2014, 4, e003866.	0.8	76
297	Review article: linaclotide for the management of irritable bowel syndrome with constipation. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 371-384.	1.9	56
298	Chronic prenatal stress epigenetically modifies spinal cord BDNF expression to induce sex-specific visceral hypersensitivity in offspring. <i>Neurogastroenterology and Motility</i> , 2014, 26, 715-730.	1.6	50
299	Review article: the economic impact of the irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1023-1034.	1.9	333
300	Effect of linaclotide in irritable bowel syndrome with constipation (IBS-C): a systematic review and meta-analysis. <i>Neurogastroenterology and Motility</i> , 2014, 26, 499-509.	1.6	54
301	Characterization of symptoms in irritable bowel syndrome with mixed bowel habit pattern. <i>Neurogastroenterology and Motility</i> , 2014, 26, 36-45.	1.6	38
302	Conducting multinational, cross-cultural research in the functional gastrointestinal disorders: issues and recommendations. A Rome Foundation working team report. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1094-1102.	1.9	36
303	Coping With Common Gastrointestinal Symptoms in the Community. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 567-578.	1.1	35
304	The Effectiveness of a Structured Educational Intervention on Disease-Related Misconception and Quality of Life in Patients With Irritable Bowel Syndrome. <i>Gastroenterology Nursing</i> , 2014, 37, 289-298.	0.2	3
305	A randomly selected population sample undergoing colonoscopy. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 268-275.	0.8	42
306	Prevalence, investigational pathways and diagnostic outcomes in differing irritable bowel syndrome subtypes. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1176-1180.	0.8	17
307	Irritable bowel syndrome: focus on otilonium bromide. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 131-137.	1.4	10
308	Revival of 5-HT3 antagonism as treatment of IBS-D?. <i>Gut</i> , 2014, 63, 1530-1532.	6.1	3
309	Diet and Irritable Bowel Syndrome, with a Focus on Appetite-Regulating Gut Hormones. , 2014, , 5-16.		5
310	The epidemiology of irritable bowel syndrome. <i>Clinical Epidemiology</i> , 2014, 6, 71.	1.5	606
311	Efficacy and safety of drotaverine hydrochloride in irritable bowel syndrome: A randomized double-blind placebo-controlled study. <i>Saudi Journal of Gastroenterology</i> , 2014, 20, 378.	0.5	24
312	Are IBD patients more likely to have a prior diagnosis of irritable bowel syndrome? Report of a case-control study in the General Practice Research Database. <i>United European Gastroenterology Journal</i> , 2014, 2, 505-512.	1.6	44

#	ARTICLE	IF	CITATIONS
313	Effects of NB001 and gabapentin on irritable bowel syndrome-induced behavioral anxiety and spontaneous pain. <i>Molecular Brain</i> , 2014, 7, 47.	1.3	69
314	Effect of Linaclotide on Severe Abdominal Symptoms in Patients With Irritable Bowel Syndrome With Constipation. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 616-623.	2.4	54
315	Linaclotide: A Review of Its Use in the Treatment of Irritable Bowel Syndrome with Constipation. <i>Drugs</i> , 2014, 74, 53-60.	4.9	13
316	Mechanisms and efficacy of dietary FODMAP restriction in IBS. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 256-266.	8.2	198
317	Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive <scp>IBS</scp> patients. <i>Neurogastroenterology and Motility</i> , 2014, 26, 705-714.	1.6	54
318	Subtypes of Irritable Bowel Syndrome in Children: Prevalence at Diagnosis and at Follow-Up. <i>Journal of Pediatrics</i> , 2014, 164, 1099-1103.e1.	0.9	42
319	Systematic review: the perceptions, diagnosis and management of irritable bowel syndrome in primary care - A Rome Foundation Working Team Report. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1133-1145.	1.9	40
320	American Gastroenterological Association Institute Technical Review on the Pharmacological Management of Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2014, 147, 1149-1172.e2.	0.6	113
321	Microscopic Colitis or Functional Bowel Disease With Diarrhea: A French Prospective Multicenter Study. <i>American Journal of Gastroenterology</i> , 2014, 109, 1461-1470.	0.2	73
322	Linaclotide: a guide to its use in irritable bowel syndrome with constipation in the EU. <i>Drugs and Therapy Perspectives</i> , 2014, 30, 342-347.	0.3	0
323	Irritable bowel syndrome: recent developments in diagnosis, pathophysiology, and treatment. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 435-443.	1.4	36
324	Mechanisms of visceral pain in health and functional gastrointestinal disorders. <i>Scandinavian Journal of Pain</i> , 2014, 5, 51-60.	0.5	25
327	Chronic Constipation, Irritable Bowel Syndrome With Constipation and Constipation With Pain/Discomfort: Similarities and Differences. <i>American Journal of Gastroenterology</i> , 2014, 109, 876-884.	0.2	75
328	Melatonin for the treatment of irritable bowel syndrome. <i>World Journal of Gastroenterology</i> , 2014, 20, 2492.	1.4	64
329	Relative risk of irritable bowel syndrome following acute gastroenteritis and associated risk factors. <i>Epidemiology and Infection</i> , 2014, 142, 1259-1268.	1.0	13
330	Dietary Agents and Phytochemicals in the Prevention and Treatment of Experimental Ulcerative Colitis. <i>Journal of Traditional and Complementary Medicine</i> , 2014, 4, 203-217.	1.5	49
331	Faecal incontinenceâ€”the hidden scourge of irritable bowel syndrome: a cross-sectional study. <i>BMJ Open Gastroenterology</i> , 2014, 1, e000002.	1.1	29
333	Interaction between ingested nutrients and gut endocrine cells in patients with irritable bowel syndrome (Review). <i>International Journal of Molecular Medicine</i> , 2014, 34, 363-371.	1.8	31

#	ARTICLE	IF	CITATIONS
334	A Grounded Guide to Gluten: How Modern Genotypes and Processing Impact Wheat Sensitivity. <i>Comprehensive Reviews in Food Science and Food Safety</i> , 2015, 14, 285-302.	5.9	79
336	Integrated medical psychiatric outpatient care in functional gastrointestinal disorders improves outcome. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 721-727.	0.8	22
337	Review article: gut-directed hypnotherapy in the management of irritable bowel syndrome and inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 1104-1115.	1.9	87
338	A cross-cultural investigation of attachment style, catastrophizing, negative pain beliefs, and symptom severity in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2015, 27, 490-500.	1.6	13
339	Hereditary angioedema presenting as irritable bowel syndrome: a case of early closure. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2015, 5, 29114.	0.4	2
340	A study of impact and prevalence of irritable bowel syndrome among medical students. <i>International Journal of Medicine and Medical Sciences</i> , 2015, 7, 139-147.	0.3	6
341	Optimal management of constipation associated with irritable bowel syndrome. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 691.	0.9	11
342	Electroacupuncture versus Moxibustion for Irritable Bowel Syndrome: A Randomized, Parallel-Controlled Trial. <i>Evidence-based Complementary and Alternative Medicine</i> , 2015, 2015, 1-12.	0.5	19
343	Psychosocial impact of irritable bowel syndrome: A brief review. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2015, 6, 120.	0.5	25
344	Burden of irritable bowel syndrome in an increasingly cost-aware National Health Service. <i>Frontline Gastroenterology</i> , 2015, 6, 246-251.	0.9	31
345	Role of the potassium chloride cotransporter isoform 2-mediated spinal chloride homeostasis in a rat model of visceral hypersensitivity. <i>American Journal of Physiology - Renal Physiology</i> , 2015, 308, G767-G778.	1.6	21
346	Visceral Pain and Psychiatric Disorders. <i>Modern Problems of Pharmacopsychiatry</i> , 2015, 30, 103-119.	2.5	15
347	Irritable Bowel Syndrome and the Small Intestinal Microflora. What We Do Know?. <i>Romanian Journal of Internal Medicine</i> , 2015, 53, 105-109.	0.4	2
348	Chronic Pain Syndromes, Mechanisms, and Current Treatments. <i>Progress in Molecular Biology and Translational Science</i> , 2015, 131, 565-611.	0.9	10
349	Illness perceptions mediate the relationship between bowel symptom severity and health-related quality of life in IBS patients. <i>Quality of Life Research</i> , 2015, 24, 1845-1856.	1.5	42
350	Abdominal Pain in Irritable Bowel Syndrome (IBS)., 2015, , 59-67.		1
351	An assessment of the human health impact of seven leading foodborne pathogens in the United States using disability adjusted life years. <i>Epidemiology and Infection</i> , 2015, 143, 2795-2804.	1.0	235
352	Incorporating FODMAP Dietary Restrictions: Help or Hype?. <i>Current Nutrition Reports</i> , 2015, 4, 214-219.	2.1	1

#	ARTICLE	IF	CITATIONS
353	Efficacy of a Chinese Herbal Medicine in Providing Adequate Relief of Constipation-predominant Irritable Bowel Syndrome: A Randomized Controlled Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1946-1954.e1.	2.4	34
355	Experiences of healing therapy in patients with irritable bowel syndrome and inflammatory bowel disease. <i>BMC Complementary and Alternative Medicine</i> , 2015, 15, 106.	3.7	11
356	Diet in irritable bowel syndrome. <i>Nutrition Journal</i> , 2015, 14, 36.	1.5	76
357	Co-occurrence of IBS and symptoms of anxiety or depression, among Norwegian twins, is influenced by both heredity and intrauterine growth. <i>BMC Gastroenterology</i> , 2015, 15, 9.	0.8	33
358	DIETA BAJA EN FODMAP EN EL SÃNDROME DE INTESTINO IRRITABLE. <i>Revista MÃ©dica ClÃnica Las Condes</i> , 2015, 26, 628-633.	0.2	0
359	Is it Time to Rethink Screening of Individuals With Symptoms of Irritable Bowel Syndrome for Celiac Disease?. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1944-1945.	2.4	0
360	Follow-up of patients with functional bowel symptoms treated with a low FODMAP diet. <i>World Journal of Gastroenterology</i> , 2016, 22, 4009.	1.4	104
361	Dietary Triggers in Irritable Bowel Syndrome: Is There a Role for Gluten?. <i>Journal of Neurogastroenterology and Motility</i> , 2016, 22, 547-557.	0.8	51
362	Diagnosis and management of functional symptoms in inflammatory bowel disease in remission. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2016, 7, 78.	0.6	34
363	Functional Constipation and Constipation-Predominant Irritable Bowel Syndrome in the General Population: Data from the GECCO Study. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-9.	0.7	19
364	Economic burden of irritable bowel syndrome in China. <i>World Journal of Gastroenterology</i> , 2016, 22, 10450.	1.4	55
365	Wheat and the irritable bowel syndrome "FODMAP levels of modern and ancient species and their retention during bread making. <i>Journal of Functional Foods</i> , 2016, 25, 257-266.	1.6	85
366	Efficacy of <i>Lactobacillus casei</i> Shirota for patients with irritable bowel syndrome. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 8-14.	0.8	49
367	Prevalence, symptom patterns and management of episodic diarrhoea in the community: a population-based survey in 11 countries. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 586-595.	1.9	9
368	Using best practice to create a pathway to improve management of irritable bowel syndrome: aiming for timely diagnosis, effective treatment and equitable care. <i>Frontline Gastroenterology</i> , 2016, 7, 323-330.	0.9	14
369	Physiology of Visceral Pain. , 2016, 6, 1609-1633.		145
370	Epidemiology and risk factors of uninvestigated dyspepsia, irritable bowel syndrome, and gastroesophageal reflux disease among students of Damascus University, Syria. <i>Journal of Epidemiology and Global Health</i> , 2016, 6, 285.	1.1	30
371	Sex-dependent activity of the spinal excitatory amino acid transporter: Role of estrous cycle. <i>Neuroscience</i> , 2016, 333, 311-319.	1.1	12

#	ARTICLE	IF	CITATIONS
372	Alterations in serotonin metabolism in the irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 272-282.	1.9	59
373	Systematic review with meta-analysis: diagnostic overlap of microscopic colitis and functional bowel disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 851-862.	1.9	47
374	Irritable bowel syndrome. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16014.	18.1	674
375	Fatigue, anxiety and depression overrule the role of oncological treatment in predicting self-reported health complaints in women with breast cancer compared to healthy controls. <i>Breast</i> , 2016, 28, 100-106.	0.9	28
376	Caring for Women with Inflammatory Bowel Disease. <i>Gastroenterology Clinics of North America</i> , 2016, 45, 303-315.	1.0	5
378	Cost-effectiveness of linaclotide compared to antidepressants in the treatment of irritable bowel syndrome with constipation in Scotland. <i>European Journal of Health Economics</i> , 2016, 17, 1091-1100.	1.4	6
379	Symptom burden and consulting behavior in patients with overlapping functional disorders in the US population. <i>United European Gastroenterology Journal</i> , 2016, 4, 413-422.	1.6	43
380	The low-FODMAP diet for irritable bowel syndrome: Lights and shadows. <i>Gastroenterology & Hepatology</i> , 2016, 39, 55-65.	0.2	34
381	Post-infectious irritable bowel syndrome (PI-IBS) after infection with Shiga-like toxin-producing <i>Escherichia coli</i> (STEC) O104:H4: A cohort study with prospective follow-up. <i>United European Gastroenterology Journal</i> , 2016, 4, 121-131.	1.6	33
382	The low-FODMAP diet for irritable bowel syndrome: Lights and shadows. <i>Gastroenterology & Hepatology</i> (English Edition), 2016, 39, 55-65.	0.0	0
383	Endocrine dysregulation in women with irritable bowel syndrome according to Rome II criteria. <i>Journal of Behavioral Medicine</i> , 2016, 39, 519-526.	1.1	7
384	Does oral L-galactosidase relieve irritable bowel symptoms?. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 16-21.	0.6	13
385	Sensitivity to wheat, gluten and FODMAPs in IBS: facts or fiction?. <i>Gut</i> , 2016, 65, 169-178.	6.1	154
386	A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D). <i>Gut</i> , 2016, 65, 91-99.	6.1	85
387	The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. <i>Gut</i> , 2017, 66, 1075-1082.	6.1	368
388	Colitis microscópica: avances para una mejor identificación en los pacientes con diarrea crónica. <i>Gastroenterology & Hepatology</i> , 2017, 40, 107-116.	0.2	4
389	Comparison of Symptoms, Healthcare Utilization, and Treatment in Diagnosed and Undiagnosed Individuals With Diarrhea-Predominant Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2017, 112, 892-899.	0.2	47
390	Improving clinical care for patients with irritable bowel syndrome. <i>British Journal of Nursing</i> , 2017, 26, 76-80.	0.3	1

#	ARTICLE	IF	CITATIONS
391	Advances for improved diagnosis of microscopic colitis in patients with chronic diarrhoea. <i>GastroenterologĀa Y HepatologĀa (English Edition)</i> , 2017, 40, 107-116.	0.0	2
392	The gut microbiota as a key regulator of visceral pain. <i>Pain</i> , 2017, 158, S19-S28.	2.0	63
393	Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 311-322.	1.4	13
394	A pragmatic randomised controlled trial of healing therapy in a gastroenterology outpatient setting. <i>European Journal of Integrative Medicine</i> , 2017, 9, 110-119.	0.8	3
395	Melatonin's role as a co-adjuvant treatment in colonic diseases: A review. <i>Life Sciences</i> , 2017, 170, 72-81.	2.0	62
397	Effect of warming moxibustion Tianshu (ST 25, bilateral) and Qihai (CV 6) for the treatment of diarrhea-dominant irritable bowel syndrome: a patient-blinded pilot trial with orthogonal design. <i>Journal of Traditional Chinese Medicine = Chung I Tsa Chih Ying Wen Pan / Sponsored By All-China Association of Traditional Chinese Medicine. Academy of Traditional Chinese Medicine</i> , 2017, 37, 538-545.	0.4	2
398	The global impact of IBS: time to think about IBS-specific models of care?. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 727-736.	1.4	33
399	<i>Saccharomyces cerevisiae</i> and <i>Kluyveromyces marxianus</i> Cocultures Allow Reduction of Fermentable Oligo-, Di-, and Monosaccharides and Polyols Levels in Whole Wheat Bread. <i>Journal of Agricultural and Food Chemistry</i> , 2017, 65, 8704-8713.	2.4	62
400	Effect of diet and individual dietary guidance on gastrointestinal endocrine cells in patients with irritable bowel syndrome (Review). <i>International Journal of Molecular Medicine</i> , 2017, 40, 943-952.	1.8	19
401	Dietary fiber in irritable bowel syndrome (Review). <i>International Journal of Molecular Medicine</i> , 2017, 40, 607-613.	1.8	103
402	Irritable Bowel Syndrome: Pain in Spain. <i>American Journal of Gastroenterology</i> , 2017, 112, 1768-1769.	0.2	2
403	Prevalence of functional gastrointestinal disorders in Mexican schoolchildren. <i>Revista De GastroenterologĀa De MĀ©xico (English Edition)</i> , 2017, 82, 13-18.	0.1	10
404	The epidemiology of irritable bowel syndrome: Symptom development over a 3Ā€year period in Denmark. A prospective, populationĀ€based cohort study. <i>Neurogastroenterology and Motility</i> , 2017, 29, e12986.	1.6	11
405	Comparative efficacy of psychological therapies for improving mental health and daily functioning in irritable bowel syndrome: A systematic review and meta-analysis. <i>Clinical Psychology Review</i> , 2017, 51, 142-152.	6.0	108
406	The impact of irritable bowel syndrome on daily functioning: Characterizing and understanding daily consequences of <sc>IBS</sc>. <i>Neurogastroenterology and Motility</i> , 2017, 29, e12982.	1.6	45
407	Prevalencia de trastornos gastrointestinales funcionales en escolares mexicanos. <i>Revista De GastroenterologĀa De MĀ©xico</i> , 2017, 82, 13-18.	0.4	30
408	Randomized controlled study of efficacy and safety of drotaverine hydrochloride in patients with irritable bowel syndrome. <i>Medicine (United States)</i> , 2017, 96, e9235.	0.4	7
409	Irritable Bowel Syndrome: Clinical Manifestations, Dietary Influences, and Management. <i>Healthcare (Switzerland)</i> , 2017, 5, 21.	1.0	32

#	ARTICLE	IF	CITATIONS
410	Effects of Transcranial Direct Current Stimulation, Transcranial Pulsed Current Stimulation, and Their Combination on Brain Oscillations in Patients with Chronic Visceral Pain: A Pilot Crossover Randomized Controlled Study. <i>Frontiers in Neurology</i> , 2017, 8, 576.	1.1	15
411	Defecation and Stools in Vegetarians. , 2017, , 473-481.		1
412	Prevalence of Irritable Bowel Syndrome and its Association with Anxiety among Medical Students at King Saud bin Abdulaziz University for Health Sciences in Riyadh. <i>Pakistan Journal of Medical Sciences</i> , 2017, 33, 33-36.	0.3	30
413	Higher prevalence of joint hypermobility in constipation predominant irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13353.	1.6	21
414	The low <sc>FODMAP</sc> diet in the management of irritable bowel syndrome: an evidenceâ€based review of <sc>FODMAP</sc> restriction, reintroduction and personalisation in clinical practice. <i>Journal of Human Nutrition and Dietetics</i> , 2018, 31, 239-255.	1.3	199
415	Are characteristics of abdominal pain helpful to identify patients with visceral hypersensitivity in irritable bowel syndrome? Results of a prospective study. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13290.	1.6	8
416	Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 980-989.	1.4	36
417	Chemical synthesis and structural analysis of guanylate cyclase C agonist linaclotide. <i>Chinese Chemical Letters</i> , 2018, 29, 1135-1138.	4.8	11
418	Evaluation of Eluxadoline Effect on Cardiac Repolarization. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 727-736.	0.8	2
419	Exchanging Social Support Online: A Longitudinal Social Network Analysis of Irritable Bowel Syndrome Patientsâ€™ Interactions on a Health Forum. <i>Journalism and Mass Communication Quarterly</i> , 2018, 95, 1033-1057.	1.4	27
420	New therapies in Irritable Bowel Syndrome. <i>Current Opinion in Gastroenterology</i> , 2018, 34, 50-56.	1.0	4
421	Rome <sc>III</sc> vs Rome <sc>IV</sc> criteria for irritable bowel syndrome: A comparison of clinical characteristics in a large cohort study. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13189.	1.6	65
422	The kinetics of gut microbial community composition in patients with irritable bowel syndrome following fecal microbiota transplantation. <i>PLoS ONE</i> , 2018, 13, e0194904.	1.1	59
423	Positive endoscopic and ultrasonographic findings in patients with symptomâ€diagnosed functional gastrointestinal disorder: Data from a Chinese crossâ€sectional study. <i>Journal of Digestive Diseases</i> , 2018, 19, 759-765.	0.7	8
424	UK clinical experience up to 52â€weeks with linaclotide for irritable bowel syndrome with constipation. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481879879.	1.4	8
425	Visceral pain: gut microbiota, a new hope?. <i>Journal of Biomedical Science</i> , 2018, 25, 73.	2.6	67
426	Physical activity in relation to irritable bowel syndrome among Iranian adults. <i>PLoS ONE</i> , 2018, 13, e0205806.	1.1	17
427	Neuromuscular electrical stimulation as an adjunctive therapy to drotaverine hydrochloride for treating patients with diarrhea-predominant irritable bowel syndrome. <i>Medicine (United States)</i> , 2018, 97, e11478.	0.4	1

#	ARTICLE	IF	CITATIONS
428	Applicability of Yeast Fermentation to Reduce Fructans and Other FODMAPs. <i>Nutrients</i> , 2018, 10, 1247.	1.7	47
429	Computer-Assisted Cognitive-Behavior Therapy in Medical Care Settings. <i>Current Psychiatry Reports</i> , 2018, 20, 92.	2.1	8
430	Cultural Factors Influencing Functional Gastrointestinal Disorders in the East. <i>Journal of Neurogastroenterology and Motility</i> , 2018, 24, 536-543.	0.8	41
431	Colonic Hypermotility in a Rat Model of Irritable Bowel Syndrome Is Associated with Upregulation of TMEM16A in Myenteric Plexus. <i>Digestive Diseases and Sciences</i> , 2018, 63, 3329-3338.	1.1	7
432	Fecal Microbiota Transplantation Is Effective in Relieving Visceral Hypersensitivity in a Postinfectious Model. <i>BioMed Research International</i> , 2018, 2018, 1-6.	0.9	10
433	Factors which affect the efficacy of hypnotherapy for IBS: Protocol for a systematic review and meta-regression. <i>European Journal of Integrative Medicine</i> , 2018, 21, 58-62.	0.8	2
434	Connecting Our Gut Feeling and How Our Gut Feels: The Role of Well-being Attributes in Irritable Bowel Syndrome. <i>Journal of Neurogastroenterology and Motility</i> , 2018, 24, 289-298.	0.8	11
435	New treatments and therapeutic targets for IBS and other functional bowel disorders. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 589-605.	8.2	99
436	<i>Kluyveromyces marxianus</i> yeast enables the production of low FODMAP whole wheat breads. <i>Food Microbiology</i> , 2018, 76, 135-145.	2.1	41
437	Epidemiology of gastrointestinal symptoms in young and middle-aged Swiss adults: prevalences and comorbidities in a longitudinal population cohort over 28 years. <i>BMC Gastroenterology</i> , 2018, 18, 21.	0.8	42
438	Efficacy and tolerability of linaclotide in the treatment of irritable bowel syndrome with constipation in a real-world setting – results from a German noninterventional study. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, 738-744.	0.2	7
439	Vortioxetine treatment for major depressive disorder with the co-morbidity of irritable bowel syndrome with diarrhoea: a case report. <i>Journal of Theoretical Social Psychology</i> , 2018, 28, 107-109.	1.2	4
440	Increased Postprandial Colonic Motility and Autonomic Nervous System Activity in Patients With Irritable Bowel Syndrome: A Prospective Study. <i>Journal of Neurogastroenterology and Motility</i> , 2018, 24, 87-95.	0.8	20
441	Funding for gastrointestinal disease research in the European Union. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 593-595.	3.7	9
442	Effect of acupuncture and its influence on visceral hypersensitivity in IBS-D patients. <i>Medicine (United States)</i> , 2018, 97, 18.	0.4	18
443	Examining the mediational role of psychological flexibility, pain catastrophizing, and visceral sensitivity in the relationship between psychological distress, irritable bowel symptom frequency, and quality of life. <i>Psychology, Health and Medicine</i> , 2018, 23, 1168-1181.	1.3	20
444	Newly developed serine protease inhibitors decrease visceral hypersensitivity in a post-inflammatory rat model for irritable bowel syndrome. <i>British Journal of Pharmacology</i> , 2018, 175, 3516-3533.	2.7	33
445	Irritable bowel symptoms, use of healthcare, costs, sickness and disability pension benefits: A long-term population-based study. <i>Scandinavian Journal of Public Health</i> , 2019, 47, 867-875.	1.2	18

#	ARTICLE	IF	CITATIONS
446	The complex interplay between gastrointestinal and psychiatric symptoms in irritable bowel syndrome: A longitudinal assessment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 713-719.	1.4	40
447	Clinical response to linaclotide at week 4 predicts sustained response in irritable bowel syndrome with constipation and improvements in digestive and extra-digestive symptoms. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481985735.	1.4	3
448	Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones. <i>Nutrients</i> , 2019, 11, 1824.	1.7	86
449	Pseudo-obstruction, enteric dysmotility and irritable bowel syndrome. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2019, 40-41, 101635.	1.0	17
450	Healthcare use by 30,000 patients with irritable bowel syndrome (IBS) in France: a 5-year retrospective and one-year prospective national observational study. <i>BMC Gastroenterology</i> , 2019, 19, 111.	0.8	13
451	Value-based Pricing for Rifaximin Increases Access of Patients With Irritable Bowel Syndrome With Diarrhea to Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2687-2695.e11.	2.4	13
452	USING BREWER'S YEAST AND GINGER IN THE MANAGEMENT OF CONSTIPATION-PREDOMINANT IRRITABLE BOWEL SYNDROME: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL. <i>Asian Journal of Pharmaceutical and Clinical Research</i> , 0, , 372-376.	0.3	2
453	Effects of Irritable Bowel Syndrome on Daily Activities Vary Among Subtypes Based on Results From the IBS in America Survey. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2471-2478.e3.	2.4	65
455	A retrospective and prospective 12-month observational study of the socioeconomic burden of moderate to severe irritable bowel syndrome with constipation in Spain. <i>Gastroenterology & Hepatology (English Edition)</i> , 2019, 42, 141-149.	0.0	0
456	Prevalence and impact of self-reported irritable bowel symptoms in the general population. <i>United European Gastroenterology Journal</i> , 2019, 7, 307-315.	1.6	56
457	Saffron: The Golden Spice with Therapeutic Properties on Digestive Diseases. <i>Nutrients</i> , 2019, 11, 943.	1.7	96
458	Non-pharmacological treatments for irritable bowel syndrome: study protocol of an umbrella review of systematic review and meta-analyses. <i>BMJ Open</i> , 2019, 9, e027778.	0.8	7
459	Gut-focused hypnotherapy for Functional Gastrointestinal Disorders: Evidence base, practical aspects, and the Manchester Protocol. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13573.	1.6	43
460	Sacral nerve modulation for irritable bowel syndrome: A randomized, double-blind, placebo-controlled crossover study. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13570.	1.6	12
462	Technological Methods for Reducing the Content of Fructan in Wheat Bread. <i>Foods</i> , 2019, 8, 663.	1.9	15
463	Effectiveness of mesalazine to treat irritable bowel syndrome. <i>Medicine (United States)</i> , 2019, 98, e16297.	0.4	14
464	Irritable Bowel Syndrome: Current and Emerging Therapies. <i>Topics in Pain Management</i> , 2019, 35, 1-9.	0.1	0
465	Stress and a sedentary lifestyle are associated with irritable bowel syndrome in medical students from Peru: a cross-sectional study. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1322-1327.	0.8	10

#	ARTICLE	IF	CITATIONS
466	Bloating in Irritable Bowel Syndrome Is Associated with Symptoms Severity, Psychological Factors, and Comorbidities. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1288-1295.	1.1	14
467	Irritable bowel syndrome, mental health, and quality of life: Data from a population-based survey in Germany (SHIP-trend). <i>Neurogastroenterology and Motility</i> , 2019, 31, e13511.	1.6	21
468	The Antioxidant, Anti-Inflammatory, and Sedative Effects of Melatonin: Results of Clinical Trials. <i>Neuroscience and Behavioral Physiology</i> , 2019, 49, 54-59.	0.2	1
469	A retrospective and prospective 12-month observational study of the socioeconomic burden of moderate to severe irritable bowel syndrome with constipation in Spain. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 141-149.	0.2	6
470	Gluten-free and low-FODMAP sourdoughs for patients with coeliac disease and irritable bowel syndrome: A clinical perspective. <i>International Journal of Food Microbiology</i> , 2019, 290, 237-246.	2.1	44
471	Epidemiological, Clinical, and Psychological Characteristics of Individuals with Self-reported Irritable Bowel Syndrome Based on the Rome IV vs Rome III Criteria. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 392-398.e2.	2.4	78
472	Stigma and irritable bowel syndrome: a taboo subject?. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 607-615.	3.7	41
473	Gastrointestinal disorders-induced pain. <i>Gene Reports</i> , 2020, 18, 100580.	0.4	1
474	Commentary: estimating the prevalence of IBS globally—past, present and future. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 198-199.	1.9	7
475	Comparing Costs and Outcomes of Treatments for Irritable Bowel Syndrome With Diarrhea: Cost-Benefit Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 136-144.e31.	2.4	21
476	Food supplements and diet as treatment options in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13951.	1.6	24
477	Prevalence and Associated Dietary Factors of Rome IV Functional Gastrointestinal Disorders in Rural Western Honduras. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3086-3095.	1.1	5
479	Effect of Acupuncture in Patients With Irritable Bowel Syndrome: A Randomized Controlled Trial. <i>Mayo Clinic Proceedings</i> , 2020, 95, 1671-1683.	1.4	55
480	Tenapanor for the treatment of irritable bowel syndrome with constipation. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 473-479.	1.3	7
481	Health-Related Quality of Life in Irritable Bowel Syndrome. <i>Gastroenterology Nursing</i> , 2020, 43, E102-E122.	0.2	29
482	Prevalence and impact of self-reported painful and non-painful constipation in the general population. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13783.	1.6	5
483	Volatomics in inflammatory bowel disease and irritable bowel syndrome. <i>EBioMedicine</i> , 2020, 54, 102725.	2.7	21
484	An approach to the care of patients with irritable bowel syndrome. <i>Cmaj</i> , 2020, 192, E275-E282.	0.9	11

#	ARTICLE	IF	CITATIONS
485	Irritable Bowel Syndrome and Gluten-Related Disorders. <i>Nutrients</i> , 2020, 12, 1117.	1.7	16
486	Expectations of IBS patients concerning disease and healthcare providers: Results of a prospective survey among members of a French patients' association. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 961-967.	0.7	10
487	Global burden of irritable bowel syndrome: trends, predictions and risk factors. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 473-486.	8.2	248
488	Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. <i>Gastroenterology</i> , 2021, 160, 99-114.e3.	0.6	913
489	The relationship between acne vulgaris and irritable bowel syndrome: A preliminary study. <i>Journal of Cosmetic Dermatology</i> , 2021, 20, 316-320.	0.8	1
490	How are perceptions of social strain and low support related to Irritable Bowel Syndrome? A Norwegian twin study. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14007.	1.6	1
491	Epidemiologic Burden and Treatment of Chronic Symptomatic Functional Bowel Disorders in the United States: A Nationwide Analysis. <i>Gastroenterology</i> , 2021, 160, 88-98.e4.	0.6	37
492	Who is to blame for the increasing prevalence of dietary sensitivity to wheat?. <i>Cereal Research Communications</i> , 2021, 49, 1-19.	0.8	4
493	The Role of Brain-Derived Neurotrophic Factor in Irritable Bowel Syndrome. <i>Frontiers in Psychiatry</i> , 2020, 11, 531385.	1.3	10
494	Gastrointestinal Disorders: Inflammatory Bowel Disease and Irritable Bowel Syndrome. , 2021, , .		0
495	The Brain-Gut-Microbiotal Axis: A framework for understanding functional GI illness and their therapeutic interventions. <i>European Journal of Internal Medicine</i> , 2021, 84, 1-9.	1.0	44
496	A randomized double-blind placebo-controlled crossover pilot study: Acute effects of the enzyme α -galactosidase on gastrointestinal symptoms in irritable bowel syndrome patients. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14094.	1.6	4
497	Mechanism of mast cell-mediated COX2-PGE2-Eps signaling pathway in visceral hypersensitivity in irritable bowel syndrome. <i>World Chinese Journal of Digestology</i> , 2021, 29, 306-311.	0.0	0
498	The role of diet in the pathophysiology and management of irritable bowel syndrome. <i>Indian Journal of Gastroenterology</i> , 2021, 40, 111-119.	0.7	10
499	Health benefits of whole grain: effects on dietary carbohydrate quality, the gut microbiome, and consequences of processing. <i>Comprehensive Reviews in Food Science and Food Safety</i> , 2021, 20, 2742-2768.	5.9	71
500	Digestive symptoms in daily life of chronic adrenal insufficiency patients are similar to irritable bowel syndrome symptoms. <i>Scientific Reports</i> , 2021, 11, 8077.	1.6	3
501	Examining the optimal cutoff values of HADS, PHQ-9 and GAD-7 as screening instruments for depression and anxiety in irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14161.	1.6	23
502	Long-term effects of fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14200.	1.6	25

#	ARTICLE	IF	CITATIONS
503	Neuro-Immune Modulation Effects of Sacral Nerve Stimulation for Visceral Hypersensitivity in Rats. <i>Frontiers in Neuroscience</i> , 2021, 15, 645393.	1.4	5
504	Ameliorating effects and mechanisms of transcutaneous auricular vagal nerve stimulation on abdominal pain and constipation. <i>JCI Insight</i> , 2021, 6, .	2.3	42
505	The Potential of <i>Kluyveromyces marxianus</i> to Produce Low-FODMAP Straight-Dough and Sourdough Bread: a Pilot-Scale Study. <i>Food and Bioprocess Technology</i> , 2021, 14, 1920-1935.	2.6	8
506	Regulation of serum microRNA expression by acupuncture in patients with diarrhea-predominant irritable bowel syndrome. <i>Acupuncture in Medicine</i> , 2022, 40, 34-42.	0.4	8
507	Colitis Induced by Colon-Cleansing Agent. <i>Case Reports in Gastroenterology</i> , 2021, 15, 621-625.	0.3	1
508	Experiences of ethnic minority patients who are living with a primary chronic bowel condition: a systematic scoping review with narrative synthesis. <i>BMC Gastroenterology</i> , 2021, 21, 322.	0.8	2
510	Subtypes and Severity of Irritable Bowel Syndrome Are Not Related to Patients' Self-Reported Dietary Triggers: Results From an Online Survey in Dutch Adults. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2021, 121, 1750-1762.e8.	0.4	8
511	Review article: the effectiveness of group and self-help hypnotherapy for irritable bowel syndrome and the implications for improving patients' choice and access to treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1389-1404.	1.9	7
512	Pharmacologic, Dietary, and Psychological Treatments for Irritable Bowel Syndrome With Constipation: Cost Utility Analysis. <i>MDM Policy and Practice</i> , 2021, 6, 238146832097841.	0.5	8
513	Intrinsic brain abnormalities of irritable bowel syndrome with diarrhea: a preliminary resting-state functional magnetic resonance imaging study. <i>BMC Medical Imaging</i> , 2021, 21, 4.	1.4	8
517	Functional Gastrointestinal Disorders: An Anthropological Perspective. , 2013, , 71-76.		1
518	Sex and gender differences in pain and its relief. , 2006, , 1181-1197.		15
521	A Novel Method to Classify and Subgroup Patients With IBS Based on Gastrointestinal Symptoms and Psychological Profiles. <i>American Journal of Gastroenterology</i> , 2021, 116, 372-381.	0.2	43
522	<i>Lactobacillus acidophilus</i> versus placebo in the symptomatic treatment of irritable bowel syndrome: the LAPIBSS randomized trial. <i>Cellular and Molecular Biology</i> , 2017, 63, 122.	0.3	8
523	Mast Cells in Irritable Bowel Syndrome: A Systematic Review. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 463-472.	0.5	29
524	Irritable Bowel Syndrome in Hungary: How do patients view their illness?. <i>Orvosi Hetilap</i> , 2009, 3, 487-498.	0.2	2
525	News in etiology and pathogenesis of irritated bowel syndrome. <i>Klinicheskaia Meditsina</i> , 2016, 94, 92-96.	0.2	4
526	Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 107-118.	0.9	41

#	ARTICLE	IF	CITATIONS
527	Association between Symptoms of Irritable Bowel Syndrome and Methane and Hydrogen on Lactulose Breath Test. <i>Journal of Korean Medical Science</i> , 2013, 28, 901.	1.1	28
528	Association of cigarette smoking with irritable bowel syndrome: A cross-sectional study. <i>Medical Journal of the Islamic Republic of Iran</i> , 2020, 34, 72.	0.9	2
529	Effects of electroacupuncture on expression of c-fos protein and N-methyl-D-aspartate receptor 1 in the rostral ventromedia medulla of rats with chronic visceral hyperalgesia. <i>Zhong Xi Yi Jie He Xue Bao</i> , 2012, 10, 416-423.	0.7	19
530	Constructive thinking, rational intelligence and irritable bowel syndrome. <i>World Journal of Gastroenterology</i> , 2009, 15, 3106.	1.4	7
531	Irritable bowel syndrome: Physicians' awareness and patients' experience. <i>World Journal of Gastroenterology</i> , 2012, 18, 3715.	1.4	39
532	Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome. <i>World Journal of Gastroenterology</i> , 2013, 19, 5787.	1.4	46
533	Irritable bowel syndrome and organic diseases: A comparative analysis of esophageal motility. <i>World Journal of Gastroenterology</i> , 2013, 19, 6408.	1.4	4
534	Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies. <i>World Journal of Gastroenterology</i> , 2014, 20, 8898-909.	1.4	27
535	Inhibitory effect of TongXie-YaoFang formula on colonic contraction in rats. <i>World Journal of Gastroenterology</i> , 2015, 21, 2912.	1.4	15
536	Visceral hypersensitivity in inflammatory bowel diseases and irritable bowel syndrome: The role of proteases. <i>World Journal of Gastroenterology</i> , 2016, 22, 10275.	1.4	37
537	Altered profiles of fecal metabolites correlate with visceral hypersensitivity and may contribute to symptom severity of diarrhea-predominant irritable bowel syndrome. <i>World Journal of Gastroenterology</i> , 2019, 25, 6416-6429.	1.4	19
538	Possible role of intestinal stem cells in the pathophysiology of irritable bowel syndrome. <i>World Journal of Gastroenterology</i> , 2020, 26, 1427-1438.	1.4	10
539	Effects of demographic factors, body mass index, alcohol drinking and smoking habits on irritable bowel syndrome: A case control study. <i>Annals of Medical and Health Sciences Research</i> , 2013, 3, 391.	0.8	26
540	Atopic dermatitis in adults and irritable bowel syndrome: A cross-sectional study. <i>Indian Journal of Dermatology</i> , 2019, 64, 355.	0.1	11
541	Will controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome?. <i>Journal of Family Medicine and Primary Care</i> , 2019, 8, 3173.	0.3	5
542	Irritable bowel syndrome is concentrated in people with higher educations in Iran: an inequality analysis. <i>Epidemiology and Health</i> , 2017, 39, e2017005.	0.8	12
543	Osteopathic manipulative treatment and nutrition: An alternative approach to the irritable bowel syndrome. <i>Health</i> , 2013, 05, 87-93.	0.1	7
544	Irritable Bowel Syndrome among Medical Students and Interns in King Faisal University. <i>Open Journal of Preventive Medicine</i> , 2017, 07, 235-246.	0.2	7

#	ARTICLE	IF	CITATIONS
545	Postprandial platelet-poor plasma 5-hydroxytryptamine concentrations during diarrhea and constipation periods of alternating type irritable bowel syndrome patients. Turkish Journal of Gastroenterology, 2011, 22, 270-278.	0.4	3
547	Butyric acid: what is the future for this old substance?. Swiss Medical Weekly, 2012, 142, w13596.	0.8	21
548	Estimating the Burden of Irritable Bowel Syndrome: Analysis of a Nationwide Korean Database. Journal of Neurogastroenterology and Motility, 2014, 20, 242-252.	0.8	32
549	A systematic review of the prevalence and risk factors of irritable bowel syndrome among medical students. Turkish Journal of Gastroenterology, 2016, 27, 10-16.	0.4	21
550	Pro-inflammatory and anti-inflammatory cytokine response in diarrhoea-predominant Irritable bowel syndrome patients. Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation, 2012, 33, 251-256.	0.0	54
551	Diferencias de sexo y género en el dolor y en su alivio. , 2007, , 1213-1230.		0
555	Psychological Co-morbidities of Irritable Bowel Syndrome. , 2011, , 385-414.		0
556	Symptoms and Their Interpretation in Patients Self-Treating Abdominal Cramping and Pain with a Spasmolytic (Butylscopolamine Bromide) – A Pharmacy-Based Survey. Pharmacology & Pharmacy, 2011, 02, 82-87.	0.2	4
557	Role of Hormones and Neuropeptides in IBS and other Gastrointestinal Disorders: Understanding Variability and Chrononutrition. The Open Nutraceuticals Journal, 2011, 4, 213-225.	0.2	3
560	Chlamydiae in Gastrointestinal Disease. , 0, , .		0
562	Functional Gastrointestinal Disease. , 0, , 54-60.		0
563	Assesment of Psychiatric Symptoms and Co-morbidities in Patients with Irritable Bowel Syndrome. West Indian Medical Journal, 2012, 61, 544-548.	0.4	9
564	Análise da eficácia do óleo de hortelã pimenta (Mentha piperita L.) na síndrome do intestino irritável: revisão baseada em evidência. Revista Brasileira De Medicina De Família E Comunidade, 2013, 8, 121-126.	0.1	1
569	Irritable Bowel Syndrome and Microbial Pathogenesis. , 2014, , 1-27.		0
570	Prevalence of anxiety among patients with irritable bowel syndrome: A pilot study. Galle Medical Journal, 2015, 20, 17.	0.1	1
571	Störungen des gastrointestinalen Systems. Springer-Lehrbuch, 2016, , 153-179.	0.1	0
573	A study of sociodemographic factors and anxiety: depressive disorders among irritable bowel syndrome patients. The Egyptian Journal of Psychiatry: Official Journal of the Egyptian Psychiatric Association, 2017, 38, 97.	0.1	3
574	The efficiency of use of probiotic monoculture Lactobacillus plantarum 299v/LV299v in maintaining the health of digestive system. Zdravstvena Zastita, 2017, 46, 54-61.	0.0	0

#	ARTICLE	IF	CITATIONS
575	Sjögren's Syndrome. , 2017, , 207-224.		0
577	A randomised controlled trial, cost-effectiveness and process evaluation of the implementation of self-management for chronic gastrointestinal disorders in primary care, and linked projects on identification and risk assessment. Programme Grants for Applied Research, 2018, 6, 1-154.	0.4	4
578	Prevalence of Irritable Bowel Syndrome among Medical Students in Hail University, Saudi Arabia. The Egyptian Journal of Hospital Medicine, 2018, 71, 2581-2584.	0.0	3
579	Improving outcomes for patients with irritable bowel syndrome in primary care, with specific focus on diet. Primary Health Care, 2018, 28, 43-48.	0.0	0
580	Effects of Irritable Bowel Syndrome (IBS) on the health-related quality of Life among Saudi Males at Al-Jouf, Kingdom of Saudi Arabia. The Egyptian Journal of Hospital Medicine, 2018, 73, 6581-6585.	0.0	2
581	The comparative study of Enterospasm efficiency and safety in patients with functional intestinal pathology. Modern Gastroenterology, 2020, .	0.1	0
582	Own body experience and parents' attitudes perceived retrospectively in patients with irritable bowel syndrome. Psychiatria Polska, 2021, 55, 1-16.	0.2	0
583	ANKALOZAN SPONDALOT HASTALARINDA ORRATL BARSAK SENDROMU SIKLI. Namik Kemal Dergisi, 2020, , .	0.0	0
584	Irritable Bowel Syndrome Prevalence among Participants of Woodstock Rock Festival in Poland Based on Rome IV Criteria Questionnaire. International Journal of Environmental Research and Public Health, 2021, 18, 11464.	1.2	2
585	Cognitive Conflicts in Functional Gastrointestinal Disorders. Revista De Psicoterapia, 2021, 32, 55-69.	0.0	1
586	Prevalence of Irritable Bowel Syndrome and its Association with Psychological Distress among Female College Students in Korea. Biomedical Science Letters, 2020, 26, 351-359.	0.0	0
587	The Effects of Group Logotherapy on the Severity of Irritable Bowel Syndrome and the Quality of Life of the Affected Patients. Practice in Clinical Psychology, 0, , 39-46.	0.1	1
588	Depression and anxiety associated with functional bowel disorders and its impact on quality of life: A cross-sectional study. Industrial Psychiatry, 2020, 29, 68.	0.3	1
589	Alterations in Gut Microbiome Composition and Function in Irritable Bowel Syndrome and Increased Probiotic Abundance with Daily Supplementation. MSystems, 2021, 6, e0121521.	1.7	12
591	Pain in the Abdomen. , 2007, , 151-164.		0
593	Prevalence of irritable bowel syndrome: a community survey. British Journal of General Practice, 2004, 54, 495-502.	0.7	178
594	Gut-directed hypnotherapy for irritable bowel syndrome: piloting a primary care-based randomised controlled trial. British Journal of General Practice, 2006, 56, 115-21.	0.7	59
595	Irritable Bowel Syndrome in Iran: SEPAHAN Systematic Review No. 1. International Journal of Preventive Medicine, 2012, 3, S1-9.	0.2	31

#	ARTICLE	IF	CITATIONS
596	Self-reported physical health, mental health, and comorbid diseases among women with irritable bowel syndrome, fibromyalgia, or both compared with healthy control respondents. <i>Journal of the American Osteopathic Association, The</i> , 2012, 112, 726-35.	1.7	9
597	Postinfectious functional gastrointestinal disorders: a focus on epidemiology and research agendas. <i>Gastroenterology and Hepatology</i> , 2013, 9, 145-57.	0.2	5
598	Epidemiological features of irritable bowel syndrome and its subtypes among Iranian adults. <i>Annals of Gastroenterology</i> , 2015, 28, 253-258.	0.4	18
599	An expert system for the diagnosis of irritable bowel syndrome. <i>Clujul Medical</i> , 2013, 86, 208-12.	0.1	0
600	An Overview of Fiber and Fiber Supplements for Irritable Bowel Syndrome. <i>Gastroenterology and Hepatology</i> , 2019, 15, 387-389.	0.2	5
601	Functional gastrointestinal disorders. Overlap syndrome Clinical guidelines of the Russian Scientific Medical Society of Internal Medicine and Gastroenterological Scientific Society of Russia. <i>Ekspiermental'naya I Klinicheskaya Gastroenterologiya</i> , 2021, , 5-117.	0.1	15
602	The Effects of Pythagorean Self-Awareness Intervention on Irritable Bowel Syndrome Patients: A Non-randomized Controlled Trial. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1337, 345-354.	0.8	0
603	Abdominal pain models: mechanisms and therapies and experimental models. , 2020, 02, .		0
604	Relevancia y necesidades del SÃndrome del Intestino Irritable (SII): comparaciÃ³n con la Enfermedad Inflamatoria Intestinal (EII).(Por favor, si no te interesa el SII IÃ©elo). <i>GastroenterologÃa Y HepatologÃa</i> , 2022, , .	0.2	0
605	The changes in prevalence and risk of irritable bowel syndrome over time in a population-based cohort, the HUNT study, Norway. <i>Scandinavian Journal of Gastroenterology</i> , 2022, , 1-7.	0.6	3
606	Factors affecting the use of herbal products in patients with Irritable Bowel Syndrome and their results: caseâ€control study. <i>BMC Gastroenterology</i> , 2022, 22, 43.	0.8	1
607	Shedding light on biological sex differences and microbiotaâ€gutâ€brain axis: a comprehensive review of its roles in neuropsychiatric disorders. <i>Biology of Sex Differences</i> , 2022, 13, 12.	1.8	34
608	New Metabolic, Digestive, and Oxidative Stress-Related Manifestations Associated with Posttraumatic Stress Disorder. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-18.	1.9	13
609	Fermentable Oligo-, Di-, and Mono-Saccharides and Polyols (FODMAPs) Consumption and Irritable Bowel Syndrome in the French NutriNet-SantÃ Cohort. <i>Nutrients</i> , 2021, 13, 4513.	1.7	4
610	Irritable bowel syndrome and microbiome; Switching from conventional diagnosis and therapies to personalized interventions. <i>Journal of Translational Medicine</i> , 2022, 20, 173.	1.8	19
611	Effects of Ellagic Acid on Oxidative Stress Index, Inflammatory Markers and Quality of Life in Patients With Irritable Bowel Syndrome: Randomized Double-blind Clinical Trial. <i>Clinical Nutrition Research</i> , 2022, 11, 98.	0.5	2
612	Prevalence of irritable bowel syndrome and its associated risk factors among university students of Bangladesh. <i>JGH Open</i> , 2022, 6, 421-426.	0.7	4
613	The relationships between IBS and perceptions of physical and mental healthâ€a Norwegian twin study. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	3

#	ARTICLE	IF	CITATIONS
614	Network Pharmacology and Bioinformatics Approach Reveals the Multi-Target Pharmacological Mechanism of <i>Fumaria indica</i> in the Treatment of Liver Cancer. <i>Pharmaceuticals</i> , 2022, 15, 654.	1.7	17
615	Approach to Diagnosis and Management of Chronic Pelvic Pain in Women. <i>Obstetrics and Gynecology Clinics of North America</i> , 2022, 49, 219-239.	0.7	14
616	<i>Saccharomyces cerevisiae</i> 3856 in irritable bowel syndrome with predominant constipation. <i>World Journal of Gastroenterology</i> , 2022, 28, 2509-2522.	1.4	10
617	AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea. <i>Gastroenterology</i> , 2022, 163, 137-151.	0.6	43
618	AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation. <i>Gastroenterology</i> , 2022, 163, 118-136.	0.6	45
619	Gut Microbiota Manipulation in Irritable Bowel Syndrome. <i>Microorganisms</i> , 2022, 10, 1332.	1.6	9
620	Risk Factors for Self-reported Irritable Bowel Syndrome With Prior Psychiatric Disorder: The Lifelines Cohort Study. <i>Journal of Neurogastroenterology and Motility</i> , 2022, 28, 442-453.	0.8	6
622	Volatile organic compound profiling as a potential biomarker in irritable bowel syndrome: A feasibility study. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	5
623	Irritable bowel syndrome in adults: Prevalence and risk factors. <i>Annals of Medicine and Surgery</i> , 2022, 81, .	0.5	2
624	Ionic Plasticity: Common Mechanistic Underpinnings of Pathology in Spinal Cord Injury and the Brain. <i>Cells</i> , 2022, 11, 2910.	1.8	4
625	Economic living standard and abdominal pain mediate the association between functional gastrointestinal disorders and depression or anxiety. <i>Neurogastroenterology and Motility</i> , 2023, 35, .	1.6	4
626	Relevance and needs of irritable bowel syndrome (IBS): Comparison with inflammatory bowel disease (IBD). (Please, if you are not interested in IBS, read it.). <i>Gastroenterology & Hepatology (English)</i> Tj ETQq1 1 0.784614 rgB0 /Overlock	0.7	14
629	A Patient with Irritable Bowel Syndrome Improved After Treatment with <i>Sosihotang</i> , <i>Jakyakgamcho-tang</i> , and Acupuncture: A Case Report. <i>The Journal of Internal Korean Medicine</i> , 2022, 43, 960-966.	0.0	0
630	Impact of Work Hours on the Quality of Life of Adult Employees With Irritable Bowel Syndrome in Saudi Arabia. <i>Cureus</i> , 2022, , .	0.2	0
631	Role of Herbal Medicine, Acupressure and Acupuncture in the Treatment of Irritable Bowel Syndrome. , 0, , .		0
632	Índice de calidad de vida percibida en pacientes con trastornos gastrointestinales funcionales en Buenos Aires, Argentina. <i>Acta Colombiana De Psicología</i> , 2022, 26, 45-55.	0.1	0
633	Practical Evaluation and Handling of Patients with Irritable Bowel Syndrome. <i>European Medical Journal Gastroenterology</i> , 0, , 48-53.	0.0	0
634	Stress and depressive symptoms in university students in Hong Kong under the pandemic: Moderating effect of positive psychological attributes. <i>Frontiers in Psychology</i> , 0, 14, .	1.1	4

#	ARTICLE	IF	CITATIONS
635	Comparison of Blood Pressure Variability among Clinical Subtypes in Irritable Bowel Syndrome Patients with Hypertension. <i>Kocaeli Üniversitesi Saġlık Bilimleri Dergisi</i> , 0, , 52-55.	0.3	0
636	Targeting the gut-brain axis in irritable bowel disease to improve cognitive function: recent knowledge and emerging therapeutic opportunities. <i>Reviews in the Neurosciences</i> , 2023, 34, 763-773.	1.4	2
637	Paclitaxel: A Valuable Tool for Inducing Visceral Pain in Preclinical Testing?. <i>International Journal of Translational Medicine</i> , 2023, 3, 108-119.	0.1	0
638	Prevalence and description of disorders of gut-brain interaction in Spain according to the results of the Rome Foundation Global Epidemiology Study. <i>Neurogastroenterology and Motility</i> , 2023, 35, .	1.6	1